am I the only one who found retatrutide harder than the injections
am I the only one who found retatrutide harder than the injections, and I want the answer with the reasoning attached rather than just the conclusion. Where the evidence actually stands, since every thread here assumes a different answer. Phase 2 reported a large mean body weight change at 48 weeks across a few…
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
Correction: TRIUMPH is the phase 3 programme.
This is the sentence the rest of the board should read first. Phase 2 is not a label.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.